TSPO

Summary

TSPO (translocator protein, HGNC:1158) is a protein-coding gene on chromosome 22q13.2, encoding Putative peripheral benzodiazepine receptor-related protein (B1AH88).

Present mainly in the mitochondrial compartment of peripheral tissues, the protein encoded by this gene interacts with some benzodiazepines and has different affinities than its endogenous counterpart. The protein is a key factor in the flow of cholesterol into mitochondria to permit the initiation of steroid hormone synthesis. Alternatively spliced transcript variants have been reported; one of the variants lacks an internal exon and is considered non-coding, and the other variants encode the same protein.

Source: NCBI Gene 706 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 24 total
• Druggable target: yes
• MANE Select transcript: NM_000714

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1158
Approved symbol	TSPO
Name	translocator protein
Location	22q13.2
Locus type	gene with protein product
Status	Approved
Aliases	PBR, MBR, PKBS, mDRC, DBI, IBP, pk18, TSPO1
Ensembl gene	ENSG00000100300
Ensembl biotype	protein_coding
OMIM	109610
Entrez	706

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 23 protein_coding, 1 retained_intron

ENST00000329563, ENST00000337554, ENST00000396265, ENST00000428336, ENST00000472378, ENST00000583777, ENST00000864330, ENST00000864331, ENST00000864332, ENST00000864333, ENST00000864334, ENST00000864335, ENST00000864336, ENST00000864337, ENST00000864338, ENST00000864339, ENST00000864340, ENST00000864341, ENST00000864342, ENST00000924335, ENST00000972386, ENST00000972387, ENST00000972388, ENST00000972389

RefSeq mRNA: 3 — MANE Select: NM_000714 NM_000714, NM_001256530, NM_001256531

CCDS: CCDS33661

Canonical transcript exons

ENST00000337554 — 4 exons

Exon	Start	End
ENSE00001106768	43151559	43151604
ENSE00001708696	43162803	43163242
ENSE00002316005	43159210	43159420
ENSE00003788871	43161052	43161190

Expression profiles

Bgee: expression breadth ubiquitous, 271 present calls, max score 99.42.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 96.2500 / max 1685.7732, expressed in 1757 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
192593	93.1008	1756
192594	1.2321	776
192595	0.4442	266
192600	0.3810	182
192597	0.3690	194
192598	0.3453	170
192596	0.2195	73
192599	0.1580	51

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.42	gold quality
esophagus mucosa	UBERON:0002469	99.32	gold quality
mucosa of transverse colon	UBERON:0004991	99.26	gold quality
gingival epithelium	UBERON:0001949	99.23	gold quality
granulocyte	CL:0000094	99.21	gold quality
monocyte	CL:0000576	99.21	gold quality
skin of abdomen	UBERON:0001416	99.20	gold quality
mononuclear cell	CL:0000842	99.15	gold quality
leukocyte	CL:0000738	99.14	gold quality
gingiva	UBERON:0001828	99.14	gold quality
pharyngeal mucosa	UBERON:0000355	99.13	gold quality
skin of leg	UBERON:0001511	99.12	gold quality
mouth mucosa	UBERON:0003729	98.82	gold quality
minor salivary gland	UBERON:0001830	98.78	gold quality
zone of skin	UBERON:0000014	98.72	gold quality
nipple	UBERON:0002030	98.67	gold quality
left coronary artery	UBERON:0001626	98.66	gold quality
body of stomach	UBERON:0001161	98.65	gold quality
ascending aorta	UBERON:0001496	98.55	gold quality
thoracic aorta	UBERON:0001515	98.55	gold quality
bone marrow	UBERON:0002371	98.54	gold quality
coronary artery	UBERON:0001621	98.53	gold quality
omental fat pad	UBERON:0010414	98.52	gold quality
penis	UBERON:0000989	98.51	gold quality
descending thoracic aorta	UBERON:0002345	98.49	gold quality
peritoneum	UBERON:0002358	98.49	gold quality
right coronary artery	UBERON:0001625	98.48	gold quality
upper leg skin	UBERON:0004262	98.46	gold quality
right lung	UBERON:0002167	98.45	gold quality
adipose tissue of abdominal region	UBERON:0007808	98.42	gold quality

Single-cell (SCXA)

Detected in 29 experiment(s), a significant marker in 23.

Experiment	Marker?	Max mean expression
E-MTAB-10042	yes	3248.91
E-CURD-112	yes	1694.14
E-HCAD-4	yes	320.36
E-HCAD-1	yes	247.19
E-CURD-122	yes	90.41
E-GEOD-125970	yes	48.26
E-HCAD-6	yes	45.82
E-MTAB-8410	yes	45.80
E-HCAD-10	yes	41.33
E-MTAB-6701	yes	40.62
E-MTAB-9467	yes	38.69
E-MTAB-9221	yes	27.91
E-HCAD-9	yes	26.34
E-GEOD-130148	yes	26.22
E-GEOD-134144	yes	25.41

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, IRF4, JUN, MYC, PPARA, SP1, SP3, SP4, SPI1, STAT3, TCF3, TP53

Literature-anchored findings (GeneRIF, showing 40)

• Overexpression of the peripheral benzodiazepine receptor is associated with colorectal cancer (PMID:12374690)
• This gene is amplified in MDA-MB-231 aggressive breast cancer cells (PMID:12547158)
• demonstrated that PBR is expressed in mesenchymal stem cells and that their ligands affect their proliferation and differentiation (PMID:14584048)
• These results indicate that elevated peripheral-type benzodiazepine receptor (PBR) expression is not common in aggressive tumors, but may be limited to certain cancers where elevated PBR expression is associated with tumor progression. (PMID:14626449)
• High expression of PBR in this patient subgroup may be used to identify a new high risk population in breast cancer for which a more specific therapy would be beneficial. (PMID:15041726)
• involvement of PBRs in human pancreatic beta-cell function and survival. (PMID:15296476)
• our results supported the hypothesis that PBR controls T-cell maturation and suggested mechanisms through which PBR may regulate thymocyte-positive selection. (PMID:15473257)
• Our results represent first evidence of PBRs in parathyroid glands and suggest for them a role in influencing PTH release. A clear trend of PBR up-regulation in parathyroid adenoma was also found. (PMID:15648546)
• the subcellular localisation of PBR defines its function and that this receptor could be a possible target for new strategies against cancer (PMID:15769477)
• Study provides new and important evidence that variation in the PBR gene influences susceptibility to panic disorder. (PMID:16511838)
• the intensity and extent of staining for PBR had a strong direct correlation with the grade of malignancy of the tumor, along with proliferative and apoptotic indices. The highest expression of PBR was in glioblastomas grade IV. (PMID:16868661)
• Our results showed an up-regulation of peripheral-type benzodiazepine receptor (PBR) in platelets of FM patients, and this seems to be related to the severity of fibromyalgic symptoms. (PMID:16919618)
• TSPO is located in mitochondrial membranes of HT-29 and reveal that its activation induces a rise in cytosolic Ca(2+), leading to the stimulation of Cl(-) secretion. (PMID:17561806)
• TSPO expression evaluation is a useful biological marker of Adult Separation Anxiety Disorder (PMID:18054208)
• These findings reveal a previously unidentified pathway of the membrane integration of MOM proteins with multiple TMSs of the PBR. (PMID:18158327)
• Sharp inhibition of apoptosis and changes in the levels of cell proliferation in tumor cells were paralleled by decreased expression of peripheral benzodiazepine receptor in patients with squamous cell carcinoma & skin melanoma. (PMID:18256758)
• VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. (PMID:18670869)
• TSPO may serve to open the mitochondrial permeability transition pore in response to anti-cancer drugs such as erucylphosphohomocholine (PMID:18791274)
• TSPO knockdown by genetic manipulation transforms the human HT29 cancer line to a more malignant type in-vitro. (PMID:18806692)
• results show variety of CNS cells capable of expressing TSPO; pattern of expression differs between normal & diseased CNS & among different diseases & cell types; microglia & macrophages remain chief cell type upregulating TSPO expression in brain disease (PMID:19077109)
• (11)C-AC-5216 is a promising PET ligand for quantifying PBR in the human brain. (PMID:19525461)
• (18)F-PBR06 is a longer-lived and promising alternative to (11)C-labeled radioligands to measure TSPOs as a biomarker of inflammation in the brain. (PMID:19525468)
• Studies in patient populations will help determine whether (11)C-DPA-713 provides better sensitivity for evaluating increased TSPO expression. (PMID:19617321)
• Two allelic variants of TSPO gene, were tested for association with the presence of adult separation anxiety disorder. (PMID:19668118)
• Blocking TSPO function in tumor cells induces cell death and denotes a survival role for TSPO in prostate cancer . (PMID:19789311)
• Results demonstrate that the Ala147Thr spontaneous amino acid substitution within TSPO is able to affect pregnenolone production, and should encourage further studies to investigate its potential role in polygenic dyslipidemias. (PMID:19846611)
• TSPO is expressed in macrophages in human carotid atherosclerosis (PMID:20056222)
• High TSPO protein levels are associated with oral cancer. (PMID:20085808)
• Overexpression of translocator protein is associated with inflammatory bowel disease. (PMID:20222126)
• reduction in [(11)C]PBR28 binding may not be interpreted simply as a reduction in TSPO density (PMID:20424634)
• Following exposure of saliva to cigarette smoke a three-fold decrease in the affinity of salivary TSPO to its specific ligand, [(3)H]PK 11195 (p < 0.01) occurred in the cellular fraction of the saliva. (PMID:20491643)
• This review focuses on the current knowledge regarding the chemicals, hormones, and molecular mechanisms regulating Tspo gene expression under physiological conditions in a tissue- and disease-specific manner. (PMID:20600583)
• These results further define TSPO as an informative marker of glial activation in multiple sclerosis (PMID:20872081)
• The present data indicate that [(11)C]vinpocetine may serve as a molecular imaging biomarker of the activity of the TSPO system (PMID:21320609)
• The translocator protein. (PMID:21498529)
• these experiments constitute the first in-depth functional analysis of the human TSPO gene promoter and its transcriptional regulation (PMID:21958735)
• An 18-kDa Translocator Protein polymorphism explains differences in binding affinity of the PET radioligand PBR28. (PMID:22008728)
• This review describes the principles of positron emission tomography (PET) imaging, the rationale and challenges in targeting the TSPO as a means of quantifying microglial activation in vivo. (PMID:22050847)
• PK 11195 exerted a suppressive effect on VDAC1 and caused an increase in TSPO gene expression or protein levels. (PMID:22127435)
• increased expression of TSPO in temporal lobe epilepsy (PMID:22238156)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tspo	ENSMUSG00000041736
rattus_norvegicus	Tspo	ENSRNOG00000010549
drosophila_melanogaster	Tspo	FBGN0031263
caenorhabditis_elegans	tspo-1	WBGENE00077771

Paralogs (1): TSPO2 (ENSG00000112212)

Protein

Protein identifiers

Putative peripheral benzodiazepine receptor-related protein — B1AH88 (reviewed: B1AH88, P30536)

All UniProt accessions (3): P30536, B1AH87, J3QLD3

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Ubiquitous.

Miscellaneous. The relatively low levels of the corresponding mRNA suggest that it might represent errors of the splicing machinery. In addition, isoform 2 is derived from a different reading frame, compared to isoform 1 and lacks homolog support.

Isoforms (2)

UniProt ID	Names	Canonical?
B1AH88-1	2, PBR-S	yes
P30536-1	1

RefSeq proteins (3): NP_000705, NP_001243459, NP_001243460 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004307	TspO_MBR	Family
IPR038330	TspO/MBR-related_sf	Homologous_superfamily

Pfam: PF03073

UniProt features (19 total): topological domain 6, transmembrane region 5, sequence variant 4, chain 2, sequence conflict 1, initiator methionine 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-B1AH88-F1	44.67	0.00
AF-P30536-F1	66.34	0.00

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-196108	Pregnenolone biosynthesis

MSigDB gene sets: 733 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, GOBP_POSITIVE_REGULATION_OF_CALCIUM_ION_TRANSPORT, GOBP_MEMBRANE_DEPOLARIZATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, GOBP_REGULATION_OF_AUTOPHAGY, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_PHOSPHATIDYLCHOLINE_METABOLIC_PROCESS, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_RESPONSE_TO_ZINC_ION, GOBP_BEHAVIOR, GOBP_STEROL_HOMEOSTASIS, GOBP_CELLULAR_RESPONSE_TO_LIPID

GO Biological Process (45): obsolete protein targeting to mitochondrion (GO:0006626), C21-steroid hormone biosynthetic process (GO:0006700), heme biosynthetic process (GO:0006783), monoatomic anion transport (GO:0006820), chloride transport (GO:0006821), steroid metabolic process (GO:0008202), glial cell migration (GO:0008347), response to xenobiotic stimulus (GO:0009410), response to manganese ion (GO:0010042), response to vitamin B1 (GO:0010266), peripheral nervous system axon regeneration (GO:0014012), adrenal gland development (GO:0030325), negative regulation of protein ubiquitination (GO:0031397), regulation of cholesterol transport (GO:0032374), response to progesterone (GO:0032570), negative regulation of tumor necrosis factor production (GO:0032720), response to testosterone (GO:0033574), regulation of cell population proliferation (GO:0042127), cholesterol homeostasis (GO:0042632), positive regulation of apoptotic process (GO:0043065), negative regulation of nitric oxide biosynthetic process (GO:0045019), behavioral response to pain (GO:0048266), regulation of steroid biosynthetic process (GO:0050810), positive regulation of mitochondrial depolarization (GO:0051901), positive regulation of calcium ion transport (GO:0051928), contact inhibition (GO:0060242), positive regulation of glial cell proliferation (GO:0060252), negative regulation of glial cell proliferation (GO:0060253), positive regulation of programmed necrotic cell death (GO:0062100), cellular response to lipopolysaccharide (GO:0071222), cellular response to zinc ion (GO:0071294), cellular hypotonic response (GO:0071476), maintenance of protein location in mitochondrion (GO:0072656), negative regulation of mitophagy (GO:1901525), negative regulation of ATP metabolic process (GO:1903579), response to acetylcholine (GO:1905144), positive regulation of reactive oxygen species metabolic process (GO:2000379), negative regulation of corticosterone secretion (GO:2000853), steroid biosynthetic process (GO:0006694), monoatomic ion transport (GO:0006811)

GO Molecular Function (6): androgen binding (GO:0005497), benzodiazepine receptor activity (GO:0008503), cholesterol binding (GO:0015485), transmembrane transporter binding (GO:0044325), cholesterol transfer activity (GO:0120020), protein binding (GO:0005515)

GO Cellular Component (6): mitochondrion (GO:0005739), mitochondrial outer membrane (GO:0005741), cytosol (GO:0005829), membrane (GO:0016020), extracellular exosome (GO:0070062), mitochondrial membrane (GO:0031966)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of steroid hormones	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
response to ketone	2
cytoplasm	2
cellular anatomical structure	2
C21-steroid hormone metabolic process	1
hormone biosynthetic process	1
steroid hormone biosynthetic process	1
porphyrin-containing compound biosynthetic process	1
heme metabolic process	1
pigment biosynthetic process	1
monoatomic ion transport	1
monoatomic anion transport	1
inorganic anion transport	1
lipid metabolic process	1
cell migration	1
gliogenesis	1
response to chemical	1
response to metal ion	1
response to vitamin	1
response to alcohol	1
response to nitrogen compound	1
axon regeneration	1
endocrine system development	1
gland development	1
protein ubiquitination	1
regulation of protein ubiquitination	1
negative regulation of protein modification by small protein conjugation or removal	1
cholesterol transport	1
regulation of sterol transport	1
response to steroid hormone	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
negative regulation of tumor necrosis factor superfamily cytokine production	1
response to lipid	1
cell population proliferation	1
regulation of cellular process	1
sterol homeostasis	1
apoptotic process	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
hormone binding	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0A1W2PPE3, A0A3B3IS91, A0A6I8MX38, A0A6I8PU40, A8MTW9, B1AH88, B3EWF7, C0HLS1, C0HMD6, H3BQW9, I3L0S3, I3L1E1, O70738, O75638, P03289, P0C880, P0DI83, P11300, P13985, P16807, P29164, P33485, P59091, P80612, Q01480, Q01900, Q3SYB3, Q5JLA7, Q5SY85, Q5T4H9, Q63003, Q6EEV4, Q6VB84, Q86SI9, Q8N1I8, Q8N1X5, Q8N319, Q8N6K4, Q8N6U2, Q8N726

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

24 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	12
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1241 predictions. Top by Δscore:

Variant	Effect	Δscore
22:43161046:TTTCA:T	acceptor_loss	1.0000
22:43161047:TTCAG:T	acceptor_loss	1.0000
22:43161049:CA:C	acceptor_loss	1.0000
22:43161050:A:AT	acceptor_loss	1.0000
22:43161051:GGT:G	acceptor_gain	1.0000
22:43161051:GGTAC:G	acceptor_gain	1.0000
22:43161186:GCTGG:G	donor_gain	1.0000
22:43161188:TGGGT:T	donor_loss	1.0000
22:43161189:GG:G	donor_gain	1.0000
22:43161189:GGGTA:G	donor_loss	1.0000
22:43161190:GG:G	donor_gain	1.0000
22:43161190:GGT:G	donor_loss	1.0000
22:43161191:GT:G	donor_loss	1.0000
22:43161192:T:TC	donor_loss	1.0000
2:119368303:CAGG:C	donor_loss	1.0000
2:119368304:AGG:A	donor_loss	1.0000
2:119368305:GGTA:G	donor_loss	1.0000
2:119368306:G:GC	donor_loss	1.0000
2:119368307:T:G	donor_loss	1.0000
2:119370737:A:AG	acceptor_gain	1.0000
2:119370738:A:AG	acceptor_gain	1.0000
2:119370739:G:GA	acceptor_gain	1.0000
2:119370739:GAAC:G	acceptor_gain	1.0000
2:119370801:AGG:A	donor_loss	1.0000
2:119370803:G:A	donor_loss	1.0000
2:119370804:T:A	donor_loss	1.0000
22:43151601:GCTG:G	donor_gain	0.9900
22:43151602:CTGGT:C	donor_loss	0.9900
22:43151604:GGT:G	donor_loss	0.9900
22:43151605:G:GG	donor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000068385 (22:43156907 A>G), RS1000072325 (22:43156897 T>C), RS1000206374 (22:43161823 T>C), RS1000402275 (22:43157031 G>A), RS1000496175 (22:43152642 G>A,C), RS1000695358 (22:43158058 C>A), RS1000907475 (22:43163593 C>T), RS1001568370 (22:43154435 T>G), RS1001879141 (22:43160320 T>A,C), RS1002150410 (22:43155671 C>G), RS1002502325 (22:43158439 C>A), RS1002505864 (22:43155297 G>A), RS1002574353 (22:43158223 A>G), RS1002610650 (22:43163671 C>A), RS1002702457 (22:43160362 T>C)

Disease associations

OMIM: gene MIM:109610 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST004609_169	Monocyte percentage of white cells	1.000000e-12
GCST004625_197	Monocyte count	4.000000e-22
GCST009391_1949	Metabolite levels	3.000000e-06
GCST90002393_593	Monocyte count	6.000000e-43
GCST90002394_210	Monocyte percentage of white cells	6.000000e-26
GCST90002407_376	White blood cell count	1.000000e-11

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007989	monocyte percentage of leukocytes
EFO:0005091	monocyte count
EFO:0010462	aspartate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5139 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

69 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression, increases methylation	9
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	decreases expression, increases expression	3
Particulate Matter	increases expression, decreases expression, increases abundance, affects cotreatment	3
methylmercuric chloride	decreases expression	2
chloropicrin	decreases expression	2
entinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Ethanol	affects cotreatment, increases expression, increases abundance	2
Cisplatin	affects expression, affects cotreatment, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
aristolochic acid I	increases expression	1
bisphenol F	increases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
mono-(2-ethylhexyl)phthalate	decreases expression, increases expression	1
cobaltous chloride	decreases expression	1
fluorotelomer alcohols	decreases expression	1
PK 11195	affects binding	1
isobutyl alcohol	affects cotreatment, increases abundance, increases expression	1
perfluorooctane sulfonic acid	increases expression	1
SSR180575	affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl)acetamide	affects binding	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pyrachlostrobin	decreases activity	1
dorsomorphin	affects cotreatment, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL6194625	Binding	Binding affinity to hTSPO at compound concentration of 10.0 uM using Eurofins-Cerep binding assay	Data for DCP probe JNJ-78911118

Cellosaurus cell lines

6 cell lines: 6 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1EB	Abcam HCT 116 TSPO KO	Cancer cell line	Male
CVCL_B2JU	Abcam HeLa TSPO KO	Cancer cell line	Female
CVCL_D1UR	Abcam U-87MG TSPO KO	Cancer cell line	Male
CVCL_E0SE	Ubigene HeLa TSPO KO	Cancer cell line	Female
CVCL_TU95	HAP1 TSPO (-) 1	Cancer cell line	Male
CVCL_TU96	HAP1 TSPO (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.